- Home
- TVGN vs IMUX Comparison
TVGN vs IMUX Comparison
Compare TVGN & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TVGN | IMUX |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.6M | 85.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TVGN | IMUX |
|---|---|---|
| Price | $0.33 | $0.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $5.00 | ★ $6.00 |
| AVG Volume (30 Days) | 1.5M | ★ 1.5M |
| Earning Date | 11-14-2025 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $0.51 |
| 52 Week High | $1.92 | $1.39 |
Technical Indicators
Market Signals| Indicator | TVGN | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 32.95 | 32.32 |
| Support Level | $0.30 | $0.51 |
| Resistance Level | $0.41 | $0.60 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 23.04 | 9.03 |
Price Performance
Historical ComparisonAbout TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.